Scarica l'app Stockscreener
0.47
3.41%
0.0155
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.4545
Aprire:
$0.455
Volume 24 ore:
646.32K
Relative Volume:
0.42
Capitalizzazione di mercato:
$12.53M
Reddito:
-
Utile/perdita netta:
$-9.10M
Rapporto P/E:
-0.1384
EPS:
-3.395
Flusso di cassa netto:
$-11.36M
1 W Prestazione:
+0.21%
1M Prestazione:
-5.34%
6M Prestazione:
-50.26%
1 anno Prestazione:
-80.66%
Intervallo 1D:
$0.445
$0.47
Intervallo di 1 settimana:
$0.44
$0.49
Portata 52W:
$0.4011
$3.85
Gt Biopharma Inc Stock (GTBP) Company Profile
Nome
Gt Biopharma Inc
Settore
Industria
Telefono
(800) 304-9888
Indirizzo
505 MONTGOMERY STREET, SAN FRANCISCO
Compare GTBP vs PSNYW, SHMD, GOODO, DWLD, QQQE
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
PSNYW
Polestar Automotive Holding Uk
|
4.50 | 350.59M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
7.26 | 465.95M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.18 | 372.90M | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
45.25 | 0 | 0 | 0 | 0 | 0.00 |
|
QQQE
Direxion NASDAQ-100 Equal Weigh
|
103.33 | 0 | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-02 | Iniziato | ROTH MKM | Buy |
| 2021-05-24 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-13 | Iniziato | B. Riley Securities | Buy |
| 2021-03-17 | Iniziato | ROTH Capital | Buy |
Gt Biopharma Inc Borsa (GTBP) Ultime notizie
GTBP Earnings History & Surprises | EPS & Revenue Results | GT BIOPHARMA INC (NASDAQ:GTBP) - ChartMill
GTBP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
GTBPForm 8-KCurrent report - ADVFN Ltd
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
GT Biopharma to restate 2025 financials after error in Greenshoe Rights accounting - Investing.com UK
GTBP: Net loss increased to $28.4M in 2025, with cash runway projected through Q4 2026 - TradingView
GT Biopharma 2025 10‑K: $0 Revenue, $(6.68) EPS, $28.35M net loss - TradingView
GT Biopharma (NASDAQ: GTBP) details cash strain, losses and $20M equity line - Stock Titan
GTBP: Net loss rose to $28.4M in 2025, with ongoing liquidity risks and urgent need for new capital - TradingView
Restatement of 2025 quarters at GT Biopharma (NASDAQ: GTBP) - Stock Titan
GT Biopharma Reports Full Year 2025 Financial Results - GlobeNewswire
Should I Buy GTBP? GTBP 2026 AnalysisIntellectia AI™ - Intellectia AI
GT Biopharma (GTBP) Gets FDA Green Light to Test New Cancer-Fighting Tech in Humans - Barchart.com
Can GT Biopharma Inc. outperform under higher oil pricesJuly 2025 Snapshot & Verified Swing Trading Watchlist - mfd.ru
Why GT Biopharma Inc. (OXIA) stock could be top winnerPortfolio Growth Summary & Technical Analysis for Trade Confirmation - mfd.ru
GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference - The Manila Times
Risk Recap: Is GT Biopharma Inc stock a top performer YTDPortfolio Return Summary & AI Forecasted Stock Moves - baoquankhu1.vn
Rate Hike: Is GT Biopharma Inc. stock a safe investment in uncertain markets2025 Trading Recap & Real-Time Stock Entry Alerts - mfd.ru
GT Biopharma (GTBP) Expected to Announce Quarterly Earnings on Friday - Defense World
How GT Biopharma Inc. stock reacts to job market dataWeekly Trade Report & Verified Short-Term Plans - mfd.ru
How do insiders feel about GT Biopharma Inc.2025 Key Highlights & Expert Verified Movement Alerts - mfd.ru
Will GT Biopharma Inc. stock remain a Wall Street favoriteProfit Target & Reliable Price Action Trade Plans - mfd.ru
How GT Biopharma Inc. stock trades before earningsStock Surge & Intraday High Probability Alerts - mfd.ru
Ellis Martin Report: GT Biopharma, Inc. (NAS - marketscreener.com
Ellis Martin Report: GT Biopharma, Inc. (NASDAQ:GTBP) Advances Platform Immuno-Oncology Strategy with FDA-Cleared Solid Tumor IND; An Interview with CEO Michael Breen - ABN Newswire
GT Biopharma Submits IND for Solid Tumor Immunotherapy Targeting Portion of $362 Billion Market as Cash Position Nearly Triples - Barchart.com
Is GT Biopharma Inc. stock a good choice for value investorsJuly 2025 Setups & Free Daily Entry Point Trade Alerts - mfd.ru
GT Biopharma, Inc. Announces FDA Clearance of Investigational New Drug for GTB-5550 TriKE, B7-H3-Targeted Natural Killer Cell Engager for Solid Tumors Expressing B7-H3 - marketscreener.com
GT Biopharma gets FDA IND clearance for GTB-5550 TRiKE, B7-H3-targeted NK engager for B7-H3+ solid tumors - marketscreener.com
GT Biopharma surges as FDA clears human trial for new cancer drug - TradingView
GT Biopharma Announces FDA Clearance for GTB-5550 Phase 1 Clinical Trial Targeting Solid Tumors Expressing B7-H3 - Quiver Quantitative
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3 - marketscreener.com
GT Biopharma Announces FDA Clearance of Investigational New - GlobeNewswire
What analysts say about GT Biopharma Inc stock2025 Top Decliners & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
GT Biopharma, Inc. (NASDAQ:GTBP) Sees Large Increase in Short Interest - Defense World
Published on: 2026-01-18 22:59:36 - baoquankhu1.vn
Hedge Fund Bets: Will GT Biopharma Inc benefit from government policy2025 Fundamental Recap & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
THE SCARCITY DOCTRINE: 5 Assets Securing the 2026 Material Cycle - The Manila Times
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape - The AI Journal
GT Biopharma submits IND application for solid tumor cancer treatment By Investing.com - Investing.com Nigeria
GT Biopharma submits IND application for solid tumor cancer treatment - Investing.com
GT Biopharma Submits IND Application for GTB-5550 to Target $362 Billion Solid Tumor Market | GTBP Stock News - Quiver Quantitative
New immune-based drug to test B7-H3 solid tumors across 7 cancers in trial - Stock Titan
EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment - Benzinga
Big Picture: Can GT Biopharma Inc stock sustain revenue growthOil Prices & Verified Momentum Stock Watchlist - Bộ Nội Vụ
RSI Check: What Wall Street predicts for GT Biopharma Inc. stock pricePortfolio Risk Report & Accurate Entry and Exit Point Alerts - Bộ Nội Vụ
Market Rankings: Will GT Biopharma Inc stock keep outperforming rivalsPortfolio Performance Report & Safe Investment Capital Preservation Plans - Bộ Nội Vụ
Is GT Biopharma Inc. stock supported by innovation pipelineEarnings Recap Summary & Fast Moving Market Watchlists - Улправда
Why GT Biopharma Inc. stock attracts high net worth investorsModel Comparison & walk-ready comfort choices - Улправда
Will GT Biopharma Inc. (OXIA) stock keep high P E multiples2025 Top Gainers & High Accuracy Investment Signals - ulpravda.ru
GT Biopharma shares advance as flagship GTB 3650 trial escalates to next dose level - MSN
Gt Biopharma Inc Azioni (GTBP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):